DNTH Dianthus Therapeutics Inc
Price (delayed)
$17.86
Market cap
$573.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.55
Enterprise value
$552.45M
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused
Highlights
The gross profit has surged by 121% year-on-year and by 16% since the previous quarter
The revenue has soared by 121% YoY and by 16% from the previous quarter
The EPS has shrunk by 136% QoQ but it has soared by 70% YoY
DNTH's debt has soared by 155% year-on-year
Dianthus Therapeutics's net income has shrunk by 95% YoY and by 27% QoQ
Key stats
What are the main financial stats of DNTH
Market
Valuations
Earnings
Shares outstanding
32.13M
Market cap
$573.76M
Enterprise value
$552.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.5
Price to sales (P/S)
95.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
88.61
Revenue
$6.24M
Gross profit
$6.24M
Operating income
-$101.86M
Net income
-$84.97M
EBIT
-$84.97M
EBITDA
-$84.56M
Free cash flow
-$78.29M
Per share
Balance sheet
Liquidity
EPS
-$2.55
EPS diluted
-$2.55
Free cash flow per share
-$2.35
Book value per share
$11.91
Revenue per share
$0.19
TBVPS
$11.23
Total assets
$374.01M
Total liabilities
$21.53M
Debt
$1.49M
Equity
$352.48M
Working capital
$262.45M
Debt to equity
0
Current ratio
15.22
Quick ratio
14.96
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-1,356.2%
Gross margin
100%
Net margin
-1,362.8%
Operating margin
-1,633.7%
Return on assets
-23%
Return on equity
-23.9%
Return on invested capital
-46.6%
Return on capital employed
-23.9%
Return on sales
-1,362.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNTH stock price
How has the Dianthus Therapeutics stock price performed over time
Intraday
6.12%
1 week
-2.24%
1 month
-17.31%
1 year
-33.08%
YTD
-18.07%
QTD
-1.54%
Financial performance
How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$6.24M
Gross profit
$6.24M
Operating income
-$101.86M
Net income
-$84.97M
Gross margin
100%
Net margin
-1,362.8%
The gross profit has surged by 121% year-on-year and by 16% since the previous quarter
The revenue has soared by 121% YoY and by 16% from the previous quarter
The operating income has plunged by 111% YoY and by 23% from the previous quarter
Dianthus Therapeutics's net income has shrunk by 95% YoY and by 27% QoQ
Growth
What is Dianthus Therapeutics's growth rate over time
Valuation
What is Dianthus Therapeutics stock price valuation
P/E
N/A
P/B
1.5
P/S
95.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
88.61
The EPS has shrunk by 136% QoQ but it has soared by 70% YoY
DNTH's equity has soared by 109% YoY and by 4.3% QoQ
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 2.2 and 17% less than its 5-year quarterly average of 1.7
The revenue has soared by 121% YoY and by 16% from the previous quarter
DNTH's P/S is 52% below its last 4 quarters average of 186.3
Efficiency
How efficient is Dianthus Therapeutics business performance
DNTH's return on invested capital has surged by 73% year-on-year and by 25% since the previous quarter
The ROE has increased by 32% YoY but it has decreased by 10% QoQ
DNTH's return on assets is up by 29% year-on-year but it is down by 10% since the previous quarter
The ROS rose by 12% YoY but it fell by 9% QoQ
Dividends
What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNTH.
Financial health
How did Dianthus Therapeutics financials performed over time
DNTH's total assets has soared by 108% YoY and by 6% QoQ
The company's total liabilities has surged by 104% YoY and by 32% QoQ
DNTH's debt is 100% smaller than its equity
DNTH's debt has soared by 155% year-on-year
DNTH's equity has soared by 109% YoY and by 4.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.